Sanofi slides J&J’s E. coli vac­cine in­to late-stage port­fo­lio, bet­ting $175M cash on de­vel­op­ment, com­mer­cial­iza­tion pact

Sanofi has added a late-stage can­di­date to its vac­cine fran­chise, pay­ing J&J’s Janssen $175 mil­lion up­front to part­ner on a shot that will pro­tect peo­ple from ex­train­testi­nal path­o­gen­ic E. coli.

Janssen be­gan a Phase III tri­al of the vac­cine in 2021. It will now co-fund R&D costs with Sanofi, which is bring­ing its man­u­fac­tur­ing and com­mer­cial­iza­tion op­er­a­tions to the ta­ble.

Un­der CEO Paul Hud­son, Sanofi has spot­light­ed vac­cines as a key part of its R&D strat­e­gy, with a goal to bring in more than €10 bil­lion ($10.48 bil­lion) in vac­cine sales by 2030. At a re­cent in­vestor event, Jean-François Tou­s­saint, Sanofi’s glob­al head of vac­cines R&D, said the French com­pa­ny now has “the largest de­vel­op­ment tool­box in the in­dus­try.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER